Black Diamond Therapeutics Investor Relations Material

Black Diamond Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision oncology therapies. The company specializes in "MasterKey" therapies, designed to target a broad range of genetically defined tumors. These therapies aim to overcome resistance to treatment, minimize toxicities associated with targeting healthy cells, and penetrate the blood-brain barrier to address central nervous system (CNS) diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.